Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Outstanding (Diluted Average): 2022-2024

Historic Shares Outstanding (Diluted Average) for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $250.1 million.

  • Taysha Gene Therapies' Shares Outstanding (Diluted Average) rose 31.92% to $353.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.3 million, marking a year-over-year increase of 31.92%. This contributed to the annual value of $250.1 million for FY2024, which is 115.41% up from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Shares Outstanding (Diluted Average) is $250.1 million, which was up 115.41% from $116.1 million recorded in FY2023.
  • Taysha Gene Therapies' Shares Outstanding (Diluted Average)'s 5-year high stood at $250.1 million during FY2024, with a 5-year trough of $44.0 million in FY2022.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $136.7 million, with a median of $116.1 million in 2023.
  • Data for Taysha Gene Therapies' Shares Outstanding (Diluted Average) shows a peak YoY soared of 164.20% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Taysha Gene Therapies' Shares Outstanding (Diluted Average) stood at $44.0 million in 2022, then skyrocketed by 164.20% to $116.1 million in 2023, then soared by 115.41% to $250.1 million in 2024.